Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel
Jason McCarthy

Jason McCarthy Analyst Performance

Senior Managing Director, Head of Biotechnology Research at Maxim Group

Jason McCarthy is a stock analyst at Maxim Group focused in the medical sector, covering 107 publicly traded companies. Over the past year, Jason McCarthy has issued 38 stock ratings, including buy and hold recommendations. While full access to Jason McCarthy's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jason McCarthy's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
663 Last 10 Years
Buy Recommendations
89.26% 582 Buy Ratings
Companies Covered
107 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy89.3%582 ratings
Hold10.7%70 ratings
Sell0.0%0 ratings

Out of 652 total stock ratings issued by Jason McCarthy at Maxim Group, the majority (89.3%) have been Buy recommendations, followed by 10.7% Hold.

Best & Worst Calls

Exchange Coverage

ExchangePercentageCount
NASDAQ
76.6% of companies on NASDAQ
82 companies
NYSEAMERICAN
10.3% of companies on NYSEAMERICAN
11 companies
OTCMKTS
7.5% of companies on OTCMKTS
8 companies
NYSE
4.7% of companies on NYSE
5 companies
TSE
0.9% of companies on TSE
1 company

Jason McCarthy, an analyst at Maxim Group, currently covers 107 companies listed on NASDAQ, NYSEAMERICAN, OTCMKTS, NYSE and TSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
103 companies		96.3%
Manufacturing
3 companies		2.8%
Industrials
1 company		0.9%

Jason McCarthy of Maxim Group specializes in stock coverage within the Medical sector, with additional focus on Manufacturing and Industrials companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
49 companies		45.8%
PHARMACEUTICAL PREPARATIONS
19 companies		17.8%
MED - DRUGS
16 companies		15.0%
MED PRODUCTS
6 companies		5.6%
BIOTECHNOLOGY
4 companies		3.7%
MEDICAL SERVICES
2 companies		1.9%
Miscellaneous
2 companies		1.9%
SURGICAL & MEDICAL INSTRUMENTS
2 companies		1.9%
SURGICAL, MEDICAL, AND DENTAL INSTRUMENTS AND SUPPLIES
1 company		0.9%
MED INSTRUMENTS
1 company		0.9%
DIAGNOSTIC SUBSTANCES
1 company		0.9%
PROTECTION - SFTY
1 company		0.9%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company		0.9%
MED - GENERIC DRG
1 company		0.9%
MEDICAL LABORATORIES
1 company		0.9%

About Jason McCarthy

Jason McCarthy, Ph.D. is a Senior Managing Director and Head of Biotechnology Research at Maxim Group. Dr. McCarthy joined Maxim Group in July 2014. Prior to joining Maxim he received his doctoral degree in Biomedical Sciences at the Albert Einstein College of Medicine. Dr. McCarthy also holds a Master’s degree in both Biomedical Research (Albert Einstein College of Medicine) and Molecular Biology (Adelphi University), as well as a B.S. in Biochemistry from Stony Brook University.

Jason McCarthy's Ratings History at Maxim Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
Export
CompanyReport DateActionReport Date Price12-Month
Price Target		Rating12-Month
Price & ROI		Details
Rezolute, Inc. stock logo
RZLT
Rezolute
6/2/2026Boost Price Target$4.00$14.00Buy
Cassava Sciences, Inc. stock logo
FLNA
Cassava Sciences
5/26/2026Reiterated Rating$1.41$5.00Buy
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
5/18/2026Initiated Coverage$5.50$20.00Buy
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
5/15/2026Boost Price Target$10.18$20.00Buy
Rezolute, Inc. stock logo
RZLT
Rezolute
5/14/2026Boost Price Target$3.49$10.00Buy
Imunon, Inc. stock logo
IMNN
Imunon
4/17/2026Set Price Target$3.09$10.00Buy
Imunon, Inc. stock logo
IMNN
Imunon
4/17/2026Initiated Coverage$3.13Buy
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
4/8/2026Downgrade$3.80Hold
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
4/8/2026Downgrade$0.82Hold
Theriva Biologics, Inc. stock logo
TOVX
Theriva Biologics
3/31/2026Upgrade$0.20$1.00Buy
MediciNova, Inc. stock logo
MNOV
MediciNova
3/23/2026Reiterated Rating$1.56$6.00Buy
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
3/12/2026Boost Price Target$5.37$10.00Buy
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
3/10/2026Upgrade$2.75Buy
Polaryx Therapeutics, Inc. stock logo
PLYX
Polaryx Therapeutics
2/27/2026Initiated Coverage$3.19$10.00Buy
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
1/23/2026Downgrade$2.92Hold
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
12/17/2025Reiterated Rating$0.86Hold
Rezolute, Inc. stock logo
RZLT
Rezolute
12/12/2025Set Price Target$1.60$4.00
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
12/4/2025Boost Price Target$23.17$50.00Buy
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
11/26/2025Upgrade$0.36Hold
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
11/26/2025Initiated Coverage$9.75$45.00Buy
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
11/19/2025Reiterated Rating$1.84Hold
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
11/3/2025Downgrade$0.13Hold
Abpro Holdings Inc. stock logo
ABP
Abpro
10/21/2025Downgrade$0.20Hold
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
10/7/2025Boost Price Target$2.02$7.00Buy
HIND
Vyome
10/2/2025Reiterated Rating$5.50$15.00Buy
HIND
Vyome
10/2/2025Reiterated Rating$5.36$15.00Buy
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
9/30/2025Upgrade$8.31$37.50Buy
Azitra, Inc. stock logo
AZTR
Azitra
9/24/2025Lower Price Target$0.73$4.00Buy
Rezolute, Inc. stock logo
RZLT
Rezolute
9/18/2025Boost Price Target$8.33$20.00Buy
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
9/12/2025Upgrade$7.74$20.00Buy
Neuphoria Therapeutics Inc. stock logo
NEUP
Neuphoria Therapeutics
9/11/2025Boost Price Target$14.06$35.00Buy
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
9/4/2025Upgrade$1.26$4.00Buy
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
8/18/2025Lower Price Target$13.78$75.00Buy
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
8/15/2025Lower Price Target$10.80$40.00Buy
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
7/23/2025Downgrade$0.71Hold
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
7/18/2025Initiated Coverage$45.20$200.00Buy
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
7/16/2025Boost Price Target$1.87$7.00Buy
INmune Bio, Inc. stock logo
INMB
INmune Bio
7/2/2025Lower Price Target$2.34$8.00Buy
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
5/23/2025Downgrade$0.72Hold
MetaVia Inc. stock logo
MTVA
MetaVia
5/19/2025Lower Price Target$7.48$33.00Buy
Trump’s New Dollar revealed (Ad)

The last time something like this happened was 1974 - a secret deal that quietly determined the financial fate of an entire generation. According to Porter Stansberry, founder of one of the largest independent financial research firms in the world, it is happening again. Fortune calls it 'the biggest change to the world's relationship with the dollar' in a generation. Stansberry says Trump's money reset - enacted through executive orders and a treaty signed by 13 nations in December 2025 called Pax Silica - could determine whether you are enriched or quietly impoverished by the shift already underway.tc pixel

Read Porter Stansberry's full briefing and find out which moves to make now
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
5/19/2025Initiated Coverage$11.80$60.00Buy
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
5/14/2025Reiterated Rating$0.24Hold
Promis Neurosciences stock logo
PMN
Promis Neurosciences
5/12/2025Initiated Coverage$12.41$75.00Buy
Theriva Biologics, Inc. stock logo
TOVX
Theriva Biologics
5/8/2025Reiterated Rating$0.81Hold
Kairos Pharma, Ltd. stock logo
KAPA
Kairos Pharma
3/27/2025Initiated Coverage$0.93$4.00Buy
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
3/25/2025Reiterated Rating$1.45Hold
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
3/21/2025Initiated Coverage$3.15$10.00Buy
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
3/10/2025Lower Price Target$0.65$3.00Buy
Abpro Holdings Inc. stock logo
ABP
Abpro
2/24/2025Initiated Coverage$23.75$120.00Buy
INmune Bio, Inc. stock logo
INMB
INmune Bio
2/13/2025Boost Price Target$9.30$30.00Buy
Novogen Limited stock logo
KZIA
Novogen
2/6/2025Initiated Coverage$7.00$15.00Buy

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Top Stock Recommendations by Brokerage